MLTX logo

MLTX
MoonLake Immunotherapeutics

4,938
Mkt Cap
$838.64M
Volume
3.18M
52W High
$62.75
52W Low
$5.95
PE Ratio
-3.53
MLTX Fundamentals
Price
$12.78
Prev Close
$11.75
Open
$11.83
50D MA
$26.13
Beta
0.51
Avg. Volume
6.18M
EPS (Annual)
-$1.89
P/B
2.59
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 8.4% - Here's Why
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 8.4% - Time to Buy...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025
CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 CLASS ACTION REMINDER: Berger...
PR Newswire·1d ago
News Placeholder
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman MLTX...
PR Newswire·1d ago
News Placeholder
MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX MoonLake...
PR Newswire·2d ago
News Placeholder
FY2025 EPS Estimates for MLTX Decreased by Leerink Partnrs
MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of MoonLake Immunotherapeutics in a research...
MarketBeat·3d ago
News Placeholder
Equities Analysts Offer Predictions for MLTX FY2025 Earnings
MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at Wedbush decreased their FY2025 EPS estimates for MoonLake Immunotherapeutics in a research report issued to clients and...
MarketBeat·3d ago
News Placeholder
FY2029 Earnings Forecast for MLTX Issued By Wedbush
MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Analysts at Wedbush decreased their FY2029 EPS estimates for MoonLake Immunotherapeutics in a research note issued to investors on Wednesday...
MarketBeat·4d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average recommendation of "Hold" by the fifteen ratings firms that are currently covering the stock, Marketbeat Ratings...
MarketBeat·5d ago
News Placeholder
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...
PR Newswire·5d ago
News Placeholder
MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics...
PR Newswire·5d ago

Latest MLTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.